US’ Bain Capital to acquire Mitsubishi Tanabe Pharma for $3.3 bn
Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma (MTPC) from Mitsubishi Chemical Group in a ~$3.3 billion carve-out deal. MTPC, a 1678-founded Osaka-based pharma firm, will operate independently, focusing on R&D, licensing, and acquisitions. The deal, led by Bain’s Asia, North America, and Life Sciences teams, is set to close in quarter three of 2025.
Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma (MTPC) from Mitsubishi Chemical Group in a ~$3.3 billion carve-out deal.
MTPC, a 1678-founded Osaka-based pharma firm, will operate independently, focusing on R&D, licensing, and acquisitions.
The deal, led by Bain’s Asia, North America, and Life Sciences teams, is set to close in quarter three of 2025.
